Literature DB >> 7534185

[125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

A P Davenport1, R E Kuc, S L Hoskins, F E Karet, F Fitzgerald.   

Abstract

1. The linear tetrapeptide radioligand, [125I]-PD151242 was used to characterize ETA receptors in human kidney which is an ETB-rich tissue. Saturation binding assays with [125I]-PD151242 revealed a single population of high affinity endothelin receptors: KD = 0.75 +/- 0.07 nM and Bmax = 48.4 +/- 1.6 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). Hill slopes were close to unity and a one site fit was preferred to a two site model. 2. ETA-receptor-selective ligands competed for [125I]-PD151242 binding with sub-nanomolar affinity: BQ123 KD = 0.43 +/- 0.10 nM, Bmax = 46.6 +/- 7.9 fmol mg-1 protein; FR139317, KD = 0.37 +/- 0.06 nM, Bmax = 39.5 +/- 6.5 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). In each case, monophasic inhibition curves were obtained and a one site fit was preferred to a two site model. The ETB-selective agonist, BQ3020 at the highest concentration tested (10 microM) inhibited binding by only 50%. The non-selective RO462005 competed for the binding of [125I]-PD151242: KD = 1.31 +/- 1.38 microM, Bmax = 33.0 +/- 9.7 fmol mg-1 protein. Endothelin-2 and sarafotoxin S6B inhibited [125I]-PD151242 binding to renal tissue whereas ET-3 and sarafotoxin S6C were less effective. Non-endothelin and non-sarafotoxin peptides did not compete. 3. No degradation of [125I]-PD151242 was detected following incubation of the ligand with renal tissue under the conditions of the binding assay. 4. Polymerase chain reaction products corresponding to the expected size for mRNA encoding ETA and ETB receptor sub-types were detected in cortex and medulla in each of the five individuals examined.5. Autoradiographical studies showed that ETA receptors visualised with ['25I]-PD151242 were mainly localized to blood vessels including interlobular and arcuate arteries, arterioles and adjacent arcuate veins. ETB receptors localized with ['251]-BQ3020 were concentrated in the medulla and the density of binding to vessels was low.6. These data suggest [251I]-PDl51242 is selective for ETA receptors in human kidney and this sub-type is mainly localized to the renal vasculature. The results provide further evidence that the human vasculature mainly expresses the ETA receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7534185      PMCID: PMC1510473          DOI: 10.1111/j.1476-5381.1994.tb17140.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.

Authors:  P Molenaar; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 2.  Endothelins: multifunctional renal peptides.

Authors:  M S Simonson
Journal:  Physiol Rev       Date:  1993-04       Impact factor: 37.312

3.  Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution.

Authors:  G O'Reilly; D S Charnock-Jones; J J Morrison; I T Cameron; A P Davenport; S K Smith
Journal:  Biochem Biophys Res Commun       Date:  1993-06-30       Impact factor: 3.575

4.  Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat.

Authors:  J P Cristol; T D Warner; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

5.  Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation.

Authors:  D M Pollock; T J Opgenorth
Journal:  Am J Physiol       Date:  1993-01

6.  An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs.

Authors:  H Nirei; K Hamada; M Shoubo; K Sogabe; Y Notsu; T Ono
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

7.  Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

Authors:  N Mino; M Kobayashi; A Nakajima; H Amano; K Shimamoto; K Ishikawa; K Watanabe; M Nishikibe; M Yano; F Ikemoto
Journal:  Eur J Pharmacol       Date:  1992-10-06       Impact factor: 4.432

8.  Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat.

Authors:  M Bigaud; J T Pelton
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

9.  BQ-153, a novel endothelin (ET)A antagonist, attenuates the renal vascular effects of endothelin-1.

Authors:  M Cirino; C Motz; J Maw; A W Ford-Hutchinson; M Yano
Journal:  J Pharm Pharmacol       Date:  1992-09       Impact factor: 3.765

10.  Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.

Authors:  P Molenaar; G O'Reilly; A Sharkey; R E Kuc; D P Harding; C Plumpton; G A Gresham; A P Davenport
Journal:  Circ Res       Date:  1993-03       Impact factor: 17.367

View more
  10 in total

Review 1.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Authors:  Eberhard Ritz; René Wenzel
Journal:  J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 10.121

4.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

5.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment.

Authors:  Neeraj Dhaun; Vanessa Melville; William Kramer; Fiona Stavros; Terrance Coyne; Suzanne Swan; Jane Goddard; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

7.  Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

Review 9.  Endothelin receptors and their antagonists.

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

Review 10.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.